Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

FDA Approves Subcutaneous Depot Formulation of Leuprolide Mesylate for Prostate Cancer

May 27th 2021

The FDA has approved a 6-month subcutaneous depot formulation of leuprolide mesylate as a ready-to-use treatment for patients with advanced prostate cancer.

FDA Approves Piflufolastat F 18 PSMA PET Imaging Agent for Prostate Cancer

May 27th 2021

The FDA has approved piflufolastat F 18 injection, a prostate-specific membrane antigen–targeted positron emission tomography imaging agent to identify suspected metastasis or recurrence of prostate cancer.

Dr. Juárez Soto on the Rationale to Analyze the Latin American Subgroup of the TITAN Trial in mHSPC

May 26th 2021

Álvaro Juárez Soto, MD, discusses the rationale to analyze the Latin American subgroup of patients with metastatic hormone-sensitive prostate cancer evaluated in the phase 3 TITAN trial.

Dr. Garg on Selecting Between Antiandrogen Agents in Nonmetastatic CRPC

May 21st 2021

Natasha Garg, DO, discusses selecting between antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Research Efforts Examining Novel Radiation Approaches Flourish at Fox Chase Cancer Center

May 21st 2021

Eric M. Horwitz, MD, FABS, FASTRO, and Stephanie E. Weiss, MD, FASTRO, highlight ongoing research efforts with radiation therapy that are generating excitement at their institution.

Radiation Strategies Blaze a Trail for Better Outcomes in CNS Cancers and Beyond

May 21st 2021

Stephanie E. Weiss, MD, FASTRO and Eric M. Horwitz, MD, FABS, FASTRO, discuss ways to leverage radiation in the treatment of central nervous system metastases, areas of active investigation, and different available strategies that are improving outcomes for patients with cancer.

Dr. Burgess on Future Directions With PARP Inhibitors in Prostate Cancer

May 20th 2021

Earle Burgess, MD, discusses future directions with PARP inhibitors in prostate cancer.

SBRT Appears to Be Safe, Feasible in Oligometastatic Disease With Multiple Metastases

May 20th 2021

Stereotactic body radiotherapy can safely be used to treat patients with oligometastatic disease with 3 to 4 metastases or 2 metastases in close proximity to each other, according to results from the phase 1 NRG-BR001 trial.

Prophylactic Pelvic Radiotherapy Significantly Improves Biochemical Failure-Free Survival, DFS in High-Risk Prostate Cancer

May 20th 2021

Prophylactic whole-pelvic radiotherapy improved biochemical failure-free survival and disease-free survival vs prostate-only radiotherapy in patients with high-risk, locally advanced prostate cancer.

Increased PSA Screening Reduces Prostate Cancer–Specific Mortality in Younger African Americans

May 19th 2021

An increase in the frequency of prostate-specific antigen (PSA) screening was associated with a nearly 25% reduction in prostate cancer–specific mortality in younger African Americans, according to data from a study presented in a presscast held ahead of the 2021 ASCO Annual Meeting.

Dr. Johnson on Racial Disparities in Outcomes Across Multiple Tumor Types

May 19th 2021

Anita Johnson, MD, FACS, discusses racial disparities in outcomes across multiple tumor types.

Dr. Ward on Adding Systemic Therapy to Radiation Therapy in Prostate Cancer

May 18th 2021

Matthew C. Ward, MD, discusses when to consider adding systemic therapy to radiation therapy in prostate cancer.

Dr. Horwitz on the Evolution of Radiation Therapy in Prostate Cancer

May 14th 2021

Eric M. Horwitz, MD, FABS, FASTRO, discusses the evolution of radiation therapy in prostate cancer.

Dr. Gomella on Using Novel Biomarkers to Inform Biopsy Vs Observation in Prostate Cancer

May 14th 2021

Leonard G. Gomella, MD, discusses using novel biomarkers to inform whether a biopsy is needed in prostate cancer.

18F-Fluciclovine-PET/CT Plus Conventional Imaging Improves Survival With Radiotherapy in Prostate Cancer

May 14th 2021

The use of 18F-fluciclovine-PET/CT in guiding salvage treatment with radiotherapy after prostatectomy reduced the likelihood of biochemical recurrence or suboptimal response to treatment in patients with prostate cancer without evidence of extrapelvic disease with conventional imaging.

Off-the-Shelf Immunotherapy ADXS-504 Under Evaluation in Biochemically Recurrent Prostate Cancer

May 12th 2021

Columbia University Irving Medical Center will partner with Advaxis, Inc. to fund a phase 1 clinical trial that seeks to examine the novel off-the-shelf neoantigen immunotherapy agent ADXS-504 in patients with biochemically recurrent prostate cancer.

FDA Grants Breakthrough Device Designation to AI-Based Focal Therapy System in Prostate Cancer

May 11th 2021

The FDA has granted a breakthrough device designation to the Avenda Health Focal Therapy System, a male “lumpectomy” product under development to treat patients with prostate cancer in office while preserving quality of life.

Dr. Zhu on Stratifying Treatments in Node-Positive Prostate Cancer

May 10th 2021

Jason Zhu, MD, discusses the process of stratifying treatments for patients with node-positive prostate cancer.

Enzalutamide Approved in Europe for Metastatic Hormone-Sensitive Prostate Cancer

May 4th 2021

The European Commission has approved enzalutamide for the treatment of adult patients with metastatic hormone-sensitive prostate cancer.

Masitinib Plus Docetaxel Improves PFS in Metastatic Castration-Resistant Prostate Cancer

April 30th 2021

The novel oral TKI masitinib in combination with docetaxel and prednisone resulted in improved progression-free survival compared with docetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer, meeting the predefined primary end point of the phase 2b/3 AB12003 trial.